Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314277 | 0.84 | GRIN2D (0.75) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19458875 | 0.79 | GRIN2D (0.33) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5327206 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| SCHEMBL25573573 | 0.76 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1160907 | 0.74 | GRIN2D (0.65) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14070452 | 0.73 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL23917147 | 0.73 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12758982 | 0.72 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8628071 | 0.72 | GRIN2D (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL9948848 | 0.72 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000047-B2 | Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses | FARMALIDER, S.A. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-9000047-B2 | Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses | FARMALIDER, S.A. (ES) | 2015-04-07 | — | — | US | disclosed |
| US-20130065966-A1 | Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses | FARMALIDER, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065966-A1 | Compound Inhibiting Activation of the Enzyme ERK 1/2 To Be Used In The Treatment Of Neurodegenerative Illnesses | MAPK1, BACE1, APP | GRIN2D 1604/4885GRIN3B 760/4885GRIN1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.